News | September 07, 2008

Inverness Medical Launches Portable Blood Testing to Warn Patients of Potential Blood Clots

September 8. 2008 - Inverness Medical Physician Diagnostics Group, a division of Inverness Medical Innovations, today launched the INRatio2 PT/INR Monitoring System, a portable device that measures blood-clotting time, also known as prothrombin time, using one drop of blood from a patient’s finger.

The INRatio2 is used by healthcare professionals and their patients in the management of warfarin, a blood-thinning drug, to monitor the effectiveness of the drug and warn of potential blood clots and other bleeding risks. Warfarin, also sold under the brand name Coumadin, is prescribed to patients to prevent blood clots, heart attacks, deep vein thrombosis, and stroke. Warfarin is the second most common cause of emergency room visits related to adverse drug events, trailing only insulin. The FDA estimates 2 million Americans start taking warfarin every year, and many will take the drug for the rest of their lives. Due to the serious bleeding risks associated with warfarin, the FDA has labeled it with a “black box” warning, informing consumers of the major and potentially fatal risks, and indicating that patients should have their PT/INR monitored regularly.

The INRatio2 PT/INR Monitoring System has been cleared by the FDA for warfarin patients to test themselves at home, offering patients quick access to their PT/INR results. The test results are then transmitted to their treating physician by telephone or the Internet. The results provide important data that helps physicians make informed warfarin dosing adjustments to ensure that patients stay within their recommended therapeutic range. Warfarin can be difficult to manage due to the wide variance in each patient’s response to the drug, in addition to factors such as diet, age, illness, and interaction with other drugs, the company said.

The INRatio2 offers many patient-friendly features, including a one-minute test time, easy single button interface, and 200-test battery life. Its simple fingerstick test procedure, light weight (9.3 oz), and individually-sealed test strip packaging enables patients to easily test themselves at home or when traveling.

For more information: www.hemosense.com

Related Content

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Overlay Init